Therapeutic cancer vaccines can be effective for treating patients, but clinical responses vary considerably from patient to patient.
Early indicators of a favorable response are crucial for making individualized treatment decisions and advancing vaccine design, but no validated biomarkers are currently available. In this study, we used glycan microarrays to profile antiglycan antibody responses induced by PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials. Although the vaccine is designed to induce T-cell responses to prostate-specific antigen, we demonstrate that this vaccine also induces humoral responses to a carbohydrate on the poxvirus, the Forssman disaccharide (GalNAcĪ±1-3GalNAcĪ²). These responses had a statistically significant correlation with overall survival in two independent sample sets (P = 0.015 and 0.008) comprising more than 100 patients. Additionally, anti-Forssman humoral responses correlated with clinical outcome in a separate study of PROSTVAC-VF combined with a radiopharmaceutical (Quadramet). Studies on control subjects demonstrated that the survival correlation was specific to the vaccine. The results provide evidence that antiglycan antibody responses may serve as early biomarkers of a favorable response to PROSTVAC-VF and offer unique insights for improving vaccine design.
Written by:
Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC. Are you the author?
Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702.
Reference: Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1749-58.
doi: 10.1073/pnas.1314722111
PubMed Abstract
PMID: 24733910
UroToday.com Prostate Cancer Immunotherapy Section
